Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in Solid Tumors (NIRADO)
NCT04779151Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Apr 2021
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in Urothelial Bladder Cancer (UBC), gastric adenocarcinoma, gastro-oesophageal adenocarcinoma (EAC), head and neck cancer (HNC), biliary tract cancer (BTC), sponsored by Gustave Roussy. Started Apr 2021; status: terminated.
02
Drugs
niraparibdostarlimab
03
Conditions
Urothelial Bladder Cancer (UBC)gastric adenocarcinomagastro-oesophageal adenocarcinoma (EAC)head and neck cancer (HNC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04779151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779151.